Role of 5-hydroxymethylcytosine in neurodegeneration

Gene

Volumn 570, Issue 1, 2015, Pages 17-24

  Sherwani, Shariq I ^a   Khan, Haseeb A ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Alzheimer's disease; Brain tumor; DNA methylation; Huntington's disease; Neurodegeneration; Parkinson's disease

Indexed keywords

5 HYDROXYMETHYLCYTOSINE; 5-HYDROXYMETHYLCYTOSINE; CYTOSINE;

ALZHEIMER DISEASE; BRAIN DEVELOPMENT; BRAIN TUMOR; DISEASE COURSE; DNA METHYLATION; GENE EXPRESSION; GENE SILENCING; HEREDITY; HUMAN; HUNTINGTON CHOREA; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; DEGENERATIVE DISEASE; GENETIC EPIGENESIS; METABOLISM; PHYSIOLOGY;

ANIMALS; CYTOSINE; DNA METHYLATION; EPIGENESIS, GENETIC; HUMANS; NEURODEGENERATIVE DISEASES;

EID: 84937728865     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2015.06.052     Document Type: Review

References (120)

1. Ai S.X., Xu Q., Hu Y.C., et al. Hypomethylation of SNCA in blood of patients with sporadic Parkinson's disease. J. Neurol. Sci. 2014, 337:123-128.
2. Al-Mahdawi S., Virmouni S.A., Pook M.A. The emerging role of 5-hydroxymethylcytosine in neurodegenerative diseases. Front. Neurosci. 2014, 8:397.
3. Arrowsmith C.H., Bountra C., Fish P.V., Lee K., Schapira M. Epigenetic protein families: a new frontier for drug discovery. Nat. Rev. Drug Discov. 2012, 11:384-400.
4. Bader Lange M.L., St Clair D., Markesbery W.R., Studzinski C.M., Murphy M.P., Butterfield D.A. Age-related loss of phospholipid asymmetry in APP (NLh)/APP (NLh) x PS-1(P264L)/PS-1(P264L) human double mutant knock-in mice: relevance to Alzheimer disease. Neurobiol. Dis. 2010, 38:104-105.
5. Barbon A., Vallini I., Barlati S. Genomic organization of the human GRIK2 gene and evidence for multiple splicing variants. Gene 2001, 274:187-197.
6. Bekris L.M., Yu C.E., Bird T.D., Tsuang D.W. Genetics of Alzheimer disease. J. Geriatr. Psychiatry Neurol. 2010, 23:213-227.
7. Bertram L., Tanzi R.E. The genetic epidemiology of neurodegenerative disease. J. Clin. Investig. 2005, 115:1449-1457.
8. Bian E.B., Zong G., Xie Y.S., Meng X.M., Huang C., Li J., Zhao B. TET family proteins: new players in gliomas. J. Neuro-Oncol. 2014, 116:429-435.
9. Biermann J., Boyle J., Pielen A., Lagrèze W.A. Histone deacetylase inhibitors sodium butyrate and valproic acid delay spontaneous cell death in purified rat retinal ganglion cells. Mol. Vis. 2011, 17:395-403.
10. Blennow K., de Leon M.J., Zetterberg H. Alzheimer's disease. Lancet 2006, 368:387-403.
11. Bolger T.A., Yao T.P. Intracellular trafficking of histone deacetylase 4 regulates neuronal cell death. J. Neurosci. 2005, 25:9544-9553.
12. Bradley-Whitman M.A., Lovell M.A. Epigenetic changes in the progression of Alzheimer's disease. Mech. Ageing Dev. 2013, 134:486-495.
13. Brookmeyer R., Johnson E., Ziegler-Graham K., Arrighi H.M. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement. 2007, 3:186-191.
14. Buckley N.J., Johnson R., Zuccato C., Bithell A., Cattaneo E. The role of REST in transcriptional and epigenetic dysregulation in Huntington's disease. Neurobiol. Dis. 2010, 39:28-39.
15. Cadena-Del-Castillo C., Valdes-Quezada C., Carmona-Aldana F., Arias C., Bermúdez-Rattoni F., Recillas-Targa F. Age-dependent increment of hydroxymethylation in the brain cortex in the triple-transgenic mouse model of Alzheimer's disease. J. Alzheimers Dis. 2014, 41:845-854.
16. Cai M., Tian J., Zhao G.H., Luo W., Zhang B.R. Study of methylation levels of parkin gene promoter in Parkinson's disease patients. Int. J. Neurosci. 2011, 121:497-502.
17. Chen H., Dzitoyeva S., Manev H. Effect of aging on 5-hydroxymethylcytosine in the mouse hippocampus. Restor. Neurol. Neurosci. 2012, 30:237-245.
18. Chen Y., Damayanti N.P., Irudayaraj J., Dunn K., Zhou F.C. Diversity of two forms of DNA methylation in the brain. Front. Genet. 2014, 5:46.
19. Cheng Y., Bernstein A., Chen D., Jin P. 5-Hydroxymethylcytosine: a new player in brain disorders?. Exp. Neurol. 2015, 268:3-9.
20. Chiang M.C., Lee Y.C., Huang C.L., Chern Y. cAMP-response element-binding protein contributes to suppression of the A2A adenosine receptor promoter by mutant Huntingtin with expanded polyglutamine residues. J. Biol. Chem. 2005, 280:14331-14340.
21. Chiang J.H., Cheng W.S., Hood L., Tian Q. An epigenetic biomarker panel for glioblastoma multiforme personalized medicine through DNA methylation analysis of human embryonic stem cell-like signature. OMICS 2014, 18:310-323.
22. Chouliaras L., Mastroeni D., Delvaux E., Grover A., Kenis G., Hof P.R., Steinbusch H.W., Coleman P.D., Rutten B.P., van den Hove D.L. Consistent decrease in global DNA methylation and hydroxymethylation in the hippocampus of Alzheimer's disease patients. Neurobiol. Aging 2013, 34:2091-2099.
23. Colquitt B.M., Allen W.E., Barnea G., Lomvardas S. Alteration of genic 5-hydroxymethyl-cytosine patterning in olfactory neurons correlates with changes in gene expression and cell identity. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:14682-14687.
24. Colussi C., Illi B., Rosati J., Spallotta F., Farsetti A., Grasselli A., Mai A., Capogrossi M.C., Gaetano C. Histone deacetylase inhibitors: keeping momentum for neuromuscular and cardiovascular diseases treatment. Pharmacol. Res. 2010, 62:3-10.
25. Condliffe D., Wong A., Troakes C., et al. Cross-region reduction in 5-hydroxymethylcytosine in Alzheimer's disease brain. Neurobiol. Aging 2014, 35:1850-1854.
26. Coppede F. The potential of epigenetic therapies in neurodegenerative diseases. Front. Genet. 2014, 5:220.
27. Coppieters N., Dieriks B.V., Lill C., Faull R.L., Curtis M.A., Dragunow M. Global changes in DNA methylation and hydroxymethylation in Alzheimer's disease human brain. Neurobiol. Aging 2014, 35:1334-1344.
28. Corti O., Lesage S., Brice A. What genetics tells us about the causes and mechanisms of Parkinson's disease. Physiol. Rev. 2011, 91:1161-1218.
29. Coupland K.G., Mellick G.D., Silburn P.A., et al. DNA methylation of the MAPT gene in Parkinson's disease cohorts and modulation by vitamin E In Vitro. Mov. Disord. 2014, 29:1606-1614.
30. D'Mello S.R. Histone deacetylases as targets for the treatment of human neurodegenerative diseases. Drug News Perspect. 2009, 22:513-524.
31. Day J.J., Sweatt J.D. DNA methylation and memory formation. Nat. Neurosci. 2010, 13:1319-1323.
32. De Mezer M., Wojciechowska M., Napierala M., Sobczak K., Krzyzosiak W.J. Mutant CAG repeats of Huntingtin transcript fold into hairpins, form nuclear foci and are targets for RNA interference. Nucleic Acids Res. 2011, 39:3852-3863.
33. Delcuve G.P., Khan D.H., Davie J.R. Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors. Clin. Epigenet. 2012, 2012(4):5.
34. Dimitrov L., Hong C.S., Yang C., Zhuang Z., Heiss J.D. New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma. Int. J. Med. Sci. 2015, 12:201-213.
35. Dzitoyeva S., Chen H., Manev H. Effect of aging on 5-hydroxymethylcytosine in brain mitochondria. Neurobiol. Aging 2012, 33:2881-2891.
36. Egger G., Liang G., Aparicio A., Jones P.A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004, 429:457-463.
37. Feng J., Zhou Y., Campbell S.L., Le T., Li E., Sweatt J.D., Silva A.J., Fan G. Dnmt1 and Dnmt3a maintain DNA methylation and regulate synaptic function in adult forebrain neurons. Nat. Neurosci. 2010, 13:423-430.
38. Fitzsimons C.P., van Bodegraven E., Schouten M., et al. Epigenetic regulation of adult neural stem cells: implications for Alzheimer's disease. Mol. Neurodegener. 2014, 9:25.
39. Franchini D.M., Schmitz K.M., Petersen-Mahrt S.K. 5-Methylcytosine DNA demethylation: more than losing a methyl group. Annu. Rev. Genet. 2012, 46:419-441.
40. Franco R., Li S., Rodriguez-Rocha H., Burns M., Panayiotidis M.I. Molecular mechanisms of pesticide-induced neurotoxicity: relevance to Parkinson's disease. Chem. Biol. Interact. 2010, 188:289-300.
41. Freund T.F., Powell J.F., Smith A.D. Tyrosine hydroxylase-immunoreactive boutons in synaptic contact with identified striatonigral neurons, with particular reference to dendritic spines. Neuroscience 1984, 13:1189-1215.
42. Gelb D.J., Oliver E., Gilman S. Diagnostic criteria for Parkinson disease. Arch. Neurol. 1999, 56:33-39.
43. Globisch D., Münzel M., Müller M., Michalakis S., Wagner M., et al. Tissue distribution of 5-hydroxymethylcytosine and search for active demethylation intermediates. PLoS One 2010, 5:e15367.
44. Gräff J., Rei D., Guan J.S., et al. An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature 2012, 483:222-226.
45. Grayson D.R., Guidotti A. The dynamics of DNA methylation in schizophrenia and related psychiatric disorders. Neuropsychopharmacology 2013, 38:138-166.
46. Hahn M.A., Qiu R., Wu X., et al. Dynamics of 5-hydroxymethylcytosine and chromatin marks in mammalian neurogenesis. Cell Rep. 2013, 3:291-300.
47. Herman J.G., Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 2003, 349:2042-2054.
48. Hernandez D.G., Nalls M.A., Gibbs J.R., et al. Distinct DNA methylation changes highly correlated with chronological age in the human brain. Hum. Mol. Genet. 2011, 20:1164-1172.
49. Huang Y., Chavez L., Chang X., Wang X., Pastora W.A., Kang J., Zepeda-Martínez J.A., Pape U.J., Jacobsen S.E., Peters B., Rao A. Distinct roles of the methylcytosine oxidases Tet1 and Tet2 in mouse embryonic stem cells. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:1361-1366.
50. Iqbal K., Jin S.G., Pfeifer G.P., Szabó P.E. Reprogramming of the paternal genome upon fertilization involves genome-wide oxidation of 5-methylcytosine. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:3642-3647.
51. Irier H.A., Jin P. Dynamics of DNA methylation in aging and Alzheimer's disease. DNA Cell Biol. 2012, 31:S42-S48.
52. Jenkins T.G., Aston K.I., Cairns B.R., Carrell D.T. Paternal aging and associated intraindividual alterations of global sperm 5-methylcytosine and 5-hydroxymethylcytosine levels. Fertil. Steril. 2013, 100:945-951.
53. Jin S.G., Kadam S., Pfeifer G.P. Examination of the specificity of DNA methylation profiling techniques towards 5-methylcytosine and 5-hydroxymethylcytosine. Nucleic Acids Res. 2010, 38:e125.
54. Jin B., Li Y., Robertson K.D. Superior or subordinate in the epigenetic hierarchy?. Genes Cancer 2011, 2:607-617.
55. Jones A.C., Yamamura Y., Almasy L., et al. Autosomal recessive juvenile Parkinsonism maps to 6q25.2-q27 in four ethnic groups: detailed genetic mapping of the linked region. Am. J. Hum. Genet. 1998, 63:80-87.
56. Jones P.A., et al. Moving AHEAD with an international human epigenome project. Nature 2008, 454:711-715.
57. Jowaed A., Schmitt I., Kaut O., Wullner U. Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains. J. Neurosci. 2010, 30:6355-6659.
58. Kaut O., Schmitt I., Wüllner U. Genome-scale methylation analysis of Parkinson's disease patients' brains reveals DNA hypomethylation and increased mRNA expression of cytochrome P450 2E1. Neurogenetics 2012, 13:87-91.
59. Kim M.S., Akhtar M.W., Adachi M., et al. An essential role for histone deacetylase 4 in synaptic plasticity and memory formation. J. Neurosci. 2012, 32:10879-10886.
60. Klein C., Westenberger A. Genetics of Parkinson's disease. Cold Spring Harb. Perspect. Med. 2012, 2:a008888.
61. Klein C.J., Botuyan M.V., Wu Y., et al. Mutations in DNMT1 cause hereditary sensory neuropathy with dementia and hearing loss. Nat. Genet. 2011, 43:595-600.
62. Knapp M., Prince M. Report-Dementia UK: London School of Economics 2007, King's College London and The Alzheimer's Society.
63. Kriaucionis S., Heintz N. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science 2009, 324:929-930.
64. Kwok J.B. Role of epigenetics in Alzheimer's and Parkinson's disease. Epigenomics 2010, 2:671-682.
65. Lazaro D.F., Rodrigues E.F., Langohr R., Shahpasandzadeh H., Ribeiro T., Guerreiro P., et al. Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation. PLoS Genet. 2014, 10:e1004741.
66. Lee J., Hwang Y.J., Shin J.Y., et al. Epigenetic regulation of cholinergic receptor M1 (CHRM1) by histone H3K9me3 impairs Ca(2+) signaling in Huntington's disease. Acta Neuropathol. 2013, 125:727-739.
67. Li J.Q., Tan L., Yu J.T. The role of the LRRK2 gene in Parkinsonism. Mol. Neurodegener. 2014, 9:47.
68. Li X., Wei W., Zhao Q.Y., Widagdo J., Baker-Andresen D., Flavell C.R., D'Alessio A., Zhang Y., Bredy T.W. Neocortical Tet3-mediated accumulation of 5-hydroxymethylcytosine promotes rapid behavioral adaptation. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:7120-7125.
69. Lill C.M., Bertram L. Towards unveiling the genetics of neurodegenerative diseases. Semin. Neurol. 2011, 31:531-541.
70. Lin Q., Ding H., Zheng Z., Gu Z., Ma J., Chen L., Chan P., Cai Y. Promoter methylation analysis of seven clock genes in Parkinson's disease. Neurosci. Lett. 2012, 507:147-150.
71. Lister R., Mukamel E.A., Nery J.R., Urich M., et al. Global epigenomic reconfiguration during mammalian brain development. Science 2013, 341:1237905.
72. Liu D.X., Nath N., Chellappan S.P., Greene L.A. Regulation of neuron survival and death by p130 and associated chromatin modifiers. Genes Dev. 2005, 19:719-732.
73. Liu Y., Jiang W., Liu J., Zhao S., Xiong J., Mao Y., Wang Y. IDH1 mutations inhibit multiple α-ketoglutarate-dependent dioxygenase activities in astroglioma. J. Neuro-Oncol. 2012, 109:253-260.
74. Liu C.C., Kanekiyo T., Xu H., Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms, and therapy. Nat. Rev. Neurol. 2013, 9:106-118.
75. Lopez S., Buil A., Ordoñez J., Souto J.C., Almasy L., Lathrop M., Soria J.M. Genome-wide linkage analysis for identifying quantitative trait loci involved in the regulation of lipoprotein a (Lpa) levels. Eur. J. Hum. Genet. 2008, 16:1372-1379.
76. Lu H., Liu X., Deng Y., Qing H. DNA methylation, a hand behind neurodegenerative diseases. Front. Aging Neurosci. 2013, 5:85.
77. Lyall D.M., Harris S.E., Bastin M.E., et al. Alzheimer's disease susceptibility genes APOE and TOMM40, and brain white matter integrity in the Lothian Birth Cohort 1936. Neurobiol. Aging 2014, 35:1513.e25-1513.e33.
78. Maleszewska M., Kaminska B. Is glioblastoma an epigenetic malignancy?. Cancers (Basel) 2013, 5:1120-1139.
79. Marie S.K.N., Shinjo S.M.O. Metabolism and brain cancer. Clinics 2011, 66:33-43.
80. Masliah E., Dumaop W., Galasko D., Desplats P. Distinctive patterns of DNA methylation associated with Parkinson disease: identification of concordant epigenetic changes in brain and peripheral blood leukocytes. Epigenetics 2013, 8:1030-1038.
81. Mastroeni D., McKee A., Grover A., Rogers J., Coleman P.D. Epigenetic differences in cortical neurons from a pair of monozygotic twins discordant for Alzheimer's disease. PLoS One 2009, 4:e6617.
82. Matrisciano F., Tueting P., Dalal I., Kadriu B., Grayson D.R., Davis J.M., Nicoletti F., Guidotti A. Epigenetic modifications of GABAergic interneurons are associated with the schizophrenia-like phenotype induced by prenatal stress in mice. Neuropharmacology 2013, 68:184-194.
83. Matsumoto L., Takuma H., Tamaoka A., Kurisaki H., Date H., Tsuji S., Iwata A. CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson's disease. PLoS One 2010, 5:e15522.
84. Mottamal M., Zheng S., Huang T.L., Wang G. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules 2015, 20:3898-3941.
85. Moussaud S., Jones D.R., Moussaud-Lamodière E.L., Delenclos M., Ross O.A., McLean P.J. Alpha-synuclein and tau: teammates in neurodegeneration?. Mol. Neurodegener. 2014, 9:43.
86. Müller T., Gessi M., Waha A., et al. Nuclear exclusion of TET1 is associated with loss of 5-hydroxymethylcytosine in IDH1 wild-type gliomas. Am. J. Pathol. 2012, 181:675-683.
87. Novak K. Epigenetics changes in cancer cells: highlights of the American Association for Cancer Research Special Conference on Chromatin, Chromosomes, and Cancer Epigenetics; November 10-14, 2004; Waikoloa, Hawaii. Medscape Gen. Med. 2004, 6:17.
88. Nugent B.M., Wright C.L., Shetty A.C., Hodes G.E., Lenz K.M., Mahurkar A., Russo S.J., Devine S.E., McCarthy M.M. Brain feminization requires active repression of masculinization via DNA methylation. Nat. Neurosci. 2015, 18:690-697.
89. Numata S., Ye T., Hyde T.M., Guitart-Navarro X., Tao R., Wininger M., Colantuoni C., Weinberger D.R., Kleinman J.E., Lipska B.K. DNA methylation signatures in development and aging of the human prefrontal cortex. Am. J. Hum. Genet. 2012, 90:260-272.
90. Orr B.A., Haffner M.C., Nelson W.G., Yegnasubramanian S., Eberhart C.G. Decreased 5-hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma. PLoS One 2012, 7:e41036.
91. Pankratz N., Foroud T. Genetics of Parkinson disease. Genet. Med. 2007, 9:801-811.
92. Parrish R.R., Albertson A.J., Buckingham S.C., Hablitz J.J., Mascia K.L., Davis H.W., Lubin F.D. Status epilepticus triggers early and late alterations in brain-derived neurotrophic factor and NMDA glutamate receptor Grin2b DNAmethylation levels in the hippocampus. Neuroscience 2013, 248C:602-609.
93. Penn N.W., Suwalski R., O'Riley C., Bojanowski K., Yura R. The presence of 5-hydroxymethylcytosine in animal deoxyribonucleic acid. Biochem. J. 1972, 126:781-790.
94. Pfeifer G.P., Kadam S., Jin S.G. 5-Hydroxymethylcytosine and its potential roles in development and cancer. Epigenetics Chromatin 2013, 6:10.
95. Plagnol V., Nalls M.A., Bras J.M., Hernandez D.G., Sharma M., Sheerin U.M., et al. A two-stage meta-analysis identifies several new loci for Parkinson's disease. PLoS Genet. 2011, 7(6):1-9.
96. Reik W., Maher E.R., Morrison P.J., Harding A.E., Simpson S.A. Age at onset in Huntington's disease and methylation at D4S95. J. Med. Genet. 1993, 30:185-188.
97. Sarkar D., Leung E.Y., Baguley B.C., Finlay G.J., Askarian-Amiri M.E. Epigenetic regulation in human melanoma: past and future. Epigenetics 2015, 10:103-121.
98. Saxena S., Caroni P. Selective neuronal vulnerability in neurodegenerative diseases: from stressor thresholds to degeneration. Neuron 2011, 71:35-48.
99. Snead D., Eliezer D. Alpha-synuclein function and dysfunction on cellular membranes. Exp. Neurobiol. 2014, 23:292-313.
100. Song C.X., Szulwach K.E., Fu Y., et al. Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. Nat. Biotechnol. 2011, 29:68-72.
101. Sperling R.A., Aisen P.S., Beckett L.A., et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:280-292.
102. Szulwach K.E., Li X., Li Y., et al. 5-hmC-mediated epigenetic dynamics during postnatal neurodevelopment and aging. Nat. Neurosci. 2011, 14:1607-1616.
103. Tahiliani M., Koh K.P., Shen Y., Pastor W.A., Bandukwala H., Brudno Y., Agarwal S., Iyer L.M., Liu D.R., Aravind L., Rao A. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009, 324:930-935.
104. Takai H., Masuda K., Sato T., et al. 5-Hydroxymethylcytosine plays a critical role in glioblastomagenesis by recruiting the CHTOP-methylosome complex. Cell Rep. 2014, 9:48-60.
105. Tan Y.Y., Wu L., Zhao Z.B., et al. Methylation of α-synuclein and leucine-rich repeat kinase 2 in leukocyte DNA of Parkinson's disease patients. Parkinsonism Relat. Disord. 2014, 20:308-313.
106. Traynelis S.F., Wollmuth L.P., McBain C.J., Menniti F.S., Vance K.M., Ogden K.K., Dingledine R. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol. Rev. 2010, 62:405-496.
107. van den Hove D.L., Chouliaras L., Rutten B.P. The role of 5-hydroxymethylcytosine in aging and Alzheimer's disease: current status and prospects for future studies. Curr. Alzheimer Res. 2012, 9:545-549.
108. Vashishtha M., Ng C.W., Yildirim F., et al. Targeting H3K4 trimethylation in Huntington disease. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:E3027-E3036.
109. Villar-Menéndez I., Blanch M., Tyebji S., Pereira-Veiga T., Albasanz J.L., Martín M., Ferrer I., Pérez-Navarro E., Barrachina M. Increased 5-methylcytosine and decreased 5-hydroxymethylcytosine levels are associated with reduced striatal A2AR levels in Huntington's disease. Neruomol. Med. 2013, 15:295-309.
110. Walker F.O. Huntington's disease. Lancet 2007, 369:218-228.
111. Wang T., Pan Q., Lin L., Szulwach K.E., Song C.X., He C., Wu H., Warren S.T., Jin P., Duan R., Li X. Genome-wide DNA hydroxymethylation changes are associated with neurodevelopmental genes in the developing human cerebellum. Hum. Mol. Genet. 2012, 21:5500-5510.
112. Wang F., Yang Y., Lin X., et al. Genome-wide loss of 5-hmC is a novel epigenetic feature of Huntington's disease. Hum. Mol. Genet. 2013, 22:3641-3653.
113. Wang H., Feng Y., Bao Z., Jiang C., Yan W., Wang Y., Zhang C., Liu Y., Zhang Q., Zhang W., Jiang C. Epigenetic silencing of KAZALD1 confers a better prognosis and is associated with malignant transformation/progression in glioma. Oncol. Rep. 2013, 30:2089-2096.
114. Wen L., Li X., Yan L., et al. Whole-genome analysis of 5-hydroxymethylcytosine and 5-methylcytosine at base resolution in the human brain. Genome Biol. 2014, 15:R49.
115. Weng Y.L., An R., Shin J., Song H., Ming G.L. DNA modifications and neurological disorders. Neurotherapeutics 2013, 10:556-567.
116. Winkelmann J., Lin L., Schormair B., et al. Mutations in DNMT1 cause autosomal dominant cerebellar ataxia, deafness and narcolepsy. Hum. Mol. Genet. 2012, 21:2205-2210.
117. Wossidlo M., Nakamura T., Lepikhov K., Marques C.J., Zakhartchenko V., Boiani M., Arand J., Nakano T., Reik W., Walter J. 5-Hydroxymethylcytosine in the mammalian zygote is linked with epigenetic reprogramming. Nat. Commun. 2011, 2:241.
118. Wu C.S., Lu Y.J., Li H.P., Hsueh C., Lu C.Y., Leu Y.W., Liu H.P., Lin K.H., Huang T.H.M., Chang Y.S. Glutamate receptor, ionotropic, kainate 2 silencing by DNA hypermethylation possesses tumor suppressor function in gastric cancer. Int. J. Cancer 2010, 126:2542-2552.
119. Xu Y., Wu F., Tan L., et al. Genome-wide regulation of 5hmC, 5mC, and gene expression by Tet1 hydroxylase in mouse embryonic stem cells. Mol. Cell 2011, 42:451-464.
120. Zhang Y., Friedlander R.M. Using non-coding small RNAs to develop therapies for Huntington's disease. Gene Ther. 2011, 18:1139-1149.